To investigate plasma metabolomic and lipidomic profiles in rheumatoid arthritis (RA) to identify potential biomarkers for distinguishing treatment responses and improving clinical outcomes.
Key Findings:
12 core features identified in the treatment non-response group included specific lipids (Cer(d18:1/16:0), PS(16:0/20:0), Palmitic acid) and metabolites (Mimosine, D-Xylose).
Identified features showed significant correlations with high disease activity.
Preliminary evidence of potential associations across different stages of disease progression.
Interpretation:
The findings suggest significant metabolic and lipidomic alterations in RA, indicating that these candidate biomarkers may serve as preliminary indicators of treatment response, potentially guiding clinical decisions.
Limitations:
Study focused on a limited sample size of RA patients.
Further validation required to confirm the utility of identified biomarkers across diverse populations.
Conclusion:
The study enhances understanding of biochemical alterations associated with treatment non-response in RA and identifies potential biomarkers for management, which could improve treatment strategies.
